JP2016538545A - 肝臓癌の診断及び予後判定のための材料及び方法 - Google Patents

肝臓癌の診断及び予後判定のための材料及び方法 Download PDF

Info

Publication number
JP2016538545A
JP2016538545A JP2016530873A JP2016530873A JP2016538545A JP 2016538545 A JP2016538545 A JP 2016538545A JP 2016530873 A JP2016530873 A JP 2016530873A JP 2016530873 A JP2016530873 A JP 2016530873A JP 2016538545 A JP2016538545 A JP 2016538545A
Authority
JP
Japan
Prior art keywords
liver
protein
cell
marker
marker proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016530873A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016538545A5 (enExample
Inventor
アンドリュー ワード マルコルム
アンドリュー ワード マルコルム
ヒューゴ ピケ イアン
ヒューゴ ピケ イアン
ジェームス ブリットン デビッド
ジェームス ブリットン デビッド
ミトラ ビクラム
ミトラ ビクラム
デビッド ヒートン ニゲル
デビッド ヒートン ニゲル
ゼン ヨー
ゼン ヨー
クアグリア アルベルト
クアグリア アルベルト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proteome Sciences PLC
Original Assignee
Electrophoretics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Electrophoretics Ltd filed Critical Electrophoretics Ltd
Publication of JP2016538545A publication Critical patent/JP2016538545A/ja
Publication of JP2016538545A5 publication Critical patent/JP2016538545A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57438Specifically defined cancers of liver, pancreas or kidney
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57423Specifically defined cancers of lung
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/60Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
JP2016530873A 2013-11-13 2014-11-13 肝臓癌の診断及び予後判定のための材料及び方法 Pending JP2016538545A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1320061.3 2013-11-13
GBGB1320061.3A GB201320061D0 (en) 2013-11-13 2013-11-13 Materials nad methods for diagnosis and prognosis of liver cancer
PCT/GB2014/053368 WO2015071669A2 (en) 2013-11-13 2014-11-13 Materials and methods for diagnosis and prognosis of liver cancer

Publications (2)

Publication Number Publication Date
JP2016538545A true JP2016538545A (ja) 2016-12-08
JP2016538545A5 JP2016538545A5 (enExample) 2018-04-12

Family

ID=49818578

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016530873A Pending JP2016538545A (ja) 2013-11-13 2014-11-13 肝臓癌の診断及び予後判定のための材料及び方法

Country Status (6)

Country Link
US (1) US20160320395A1 (enExample)
EP (1) EP3069142A2 (enExample)
JP (1) JP2016538545A (enExample)
CA (1) CA2928510A1 (enExample)
GB (1) GB201320061D0 (enExample)
WO (1) WO2015071669A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019537108A (ja) * 2016-10-05 2019-12-19 ユーイーエー エンタープライジズ リミテッド 癌の分類および予後
JP2021173529A (ja) * 2020-04-17 2021-11-01 合同会社H.U.グループ中央研究所 胆管がんのバイオマーカー

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105288659B (zh) * 2015-06-01 2019-07-26 北京泱深生物信息技术有限公司 Tenm1基因及其表达产物在诊治乳头状腺癌的应用
KR101750411B1 (ko) * 2015-07-10 2017-06-27 한국생명공학연구원 엑소좀 단백질 eif3a 특이반응 오토항체검출용 항원 조성물 및 이를 이용한 간암진단법
FR3048780B1 (fr) * 2016-03-11 2020-11-06 Commissariat Energie Atomique Procede de diagnostic in vitro d'atteintes hepatiques
EP3403100B1 (fr) * 2016-01-15 2020-03-11 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Procédé de diagnostic in vitro d'atteintes hépatiques
GB201619954D0 (en) * 2016-11-25 2017-01-11 Oncimmune Ltd Antibody assay
KR102712656B1 (ko) 2017-01-23 2024-10-04 리제너론 파마슈티칼스 인코포레이티드 Hsd17b13 변종 및 이것의 용도
CN115266962B (zh) * 2017-03-31 2024-05-31 北京谷海天目生物医学科技有限公司 蛋白标志物在制备弥漫型胃癌分子分型的产品中的应用及弥漫型胃癌分子分型的分类器
US11479802B2 (en) 2017-04-11 2022-10-25 Regeneron Pharmaceuticals, Inc. Assays for screening activity of modulators of members of the hydroxy steroid (17-beta) dehydrogenase (HSD17B) family
WO2018189215A1 (en) * 2017-04-12 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the survival time of a patient suffering from hepatocellular carcinoma
AU2018348195B2 (en) 2017-10-11 2025-05-15 Regeneron Pharmaceuticals, Inc. Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
CN109596829A (zh) * 2017-12-07 2019-04-09 南京医科大学 一种肝癌标志蛋白及其检测方法
WO2019115679A1 (en) * 2017-12-13 2019-06-20 Fundació Institut D'investigació En Ciències De La Salut Germans Trias I Pujol A signature to assess prognosis and therapeutic regimen in liver cancer
BR112020018758A2 (pt) 2018-03-21 2021-01-26 Regeneron Pharmaceuticals, Inc. agente de ácido ribonucleico de fita dupla, célula, vetor, composição farmacêutica, e, métodos para inibição da expressão de 17¿-hidroxiesteroide desidrogenases tipo 13, para tratamento de um indivíduo, para prevenção de um sintoma em um indivíduo, para redução do risco de desenvolver doença hepática crônica, para inibição da progressão de esteatose, para inibição do acúmulo de gotículas de lipídios
US20220244263A1 (en) * 2019-05-28 2022-08-04 The Regents Of The University Of California Methods for treating small cell neuroendocrine and related cancers
CA3166923A1 (en) * 2020-02-10 2021-08-19 Somalogic Operating Co., Inc. Nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
EP4115181A1 (en) * 2020-03-02 2023-01-11 Université de Strasbourg Method for diagnosis and/or prognosis of liver disease progression and risk of hepatocellular carcinoma and discovery of therapeutic compounds and targets to treat liver disease and cancer
CN111748624B (zh) * 2020-06-08 2022-11-04 郑州大学第一附属医院 用于预测肝癌是否复发的生物标志物
CN111748623B (zh) * 2020-06-08 2022-11-04 郑州大学第一附属医院 肝癌患者是否复发的预测标志物及试剂盒
CN112961916B (zh) * 2020-11-10 2024-03-12 上海市肿瘤研究所 Akr1c3作为肝癌预后的生物学标志物及其应用
CN112908470B (zh) * 2021-02-08 2023-10-03 深圳市人民医院 一种基于rna结合蛋白基因的肝细胞癌预后评分系统及其应用
CN113462777A (zh) * 2021-06-28 2021-10-01 武汉大学 P4hb在制备肝细胞癌早期诊断试剂盒及制备或筛选抗肝癌药物中的应用
CN114814001B (zh) * 2022-03-31 2023-02-21 武汉大学 用于制备肝癌检测试剂的新型代谢标志物及其应用
CN115754290A (zh) * 2022-09-26 2023-03-07 浙江大学 一种用于检测早期肝癌的试剂盒
CN115807089B (zh) * 2022-11-14 2024-09-13 石河子大学 肝细胞肝癌预后生物标志物及应用
CN116338189B (zh) * 2023-01-16 2025-08-22 浙江大学医学院附属第一医院 具有蛋白激酶功能的肿瘤标志物ckb在制备肿瘤诊断产品中的应用
CN116386715A (zh) * 2023-03-09 2023-07-04 福建医科大学孟超肝胆医院 用于原发性肝细胞癌蛋白质组分子分型诊断的特征蛋白及其应用
CN117607438A (zh) * 2023-11-23 2024-02-27 浙江大学 一种肝细胞癌鉴别诊断和分化程度检测方法
CN119314683B (zh) * 2024-12-17 2025-02-25 吉林大学第一医院 一种用于肝移植术后预测系统

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008522624A (ja) * 2004-12-09 2008-07-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘミアスタリン(hemiasterlin)アナログを使用する癌治療におけるチューブリンのアイソタイプのスクリーニング
JP2008522623A (ja) * 2004-12-09 2008-07-03 エーザイ株式会社 ハリコンドリンbアナログを使用した癌治療でのチューブリンアイソタイプのスクリーニング
WO2009113495A1 (ja) * 2008-03-12 2009-09-17 財団法人ヒューマンサイエンス振興財団 肝癌特異的発現遺伝子による肝癌の検査方法並びに肝癌の治療及び予防剤
WO2011078311A1 (ja) * 2009-12-25 2011-06-30 大鵬薬品工業株式会社 肝細胞癌治療のための抗腫瘍剤又は術後補助化学療法剤
WO2013033609A2 (en) * 2011-08-31 2013-03-07 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
KR970002255B1 (ko) 1990-06-11 1997-02-26 넥스스타 파아마슈티컬드, 인크. 핵산 리간드
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE60239962D1 (de) 2001-08-14 2011-06-16 Harvard College Absolute quantifizierung von proteinen und modifizierten formen davon mittels mehrstufiger massenspektrometrie
US20080161203A1 (en) * 2006-12-27 2008-07-03 Su Chun-Lin Markers identified for liver fibrosis and cirrhosis and the microarray panel thereof
GB0704764D0 (en) 2007-03-12 2007-04-18 Electrophoretics Ltd Isobarically labelled reagents and methods of their use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008522624A (ja) * 2004-12-09 2008-07-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘミアスタリン(hemiasterlin)アナログを使用する癌治療におけるチューブリンのアイソタイプのスクリーニング
JP2008522623A (ja) * 2004-12-09 2008-07-03 エーザイ株式会社 ハリコンドリンbアナログを使用した癌治療でのチューブリンアイソタイプのスクリーニング
WO2009113495A1 (ja) * 2008-03-12 2009-09-17 財団法人ヒューマンサイエンス振興財団 肝癌特異的発現遺伝子による肝癌の検査方法並びに肝癌の治療及び予防剤
WO2011078311A1 (ja) * 2009-12-25 2011-06-30 大鵬薬品工業株式会社 肝細胞癌治療のための抗腫瘍剤又は術後補助化学療法剤
WO2013033609A2 (en) * 2011-08-31 2013-03-07 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of cancer

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019537108A (ja) * 2016-10-05 2019-12-19 ユーイーエー エンタープライジズ リミテッド 癌の分類および予後
JP2023003422A (ja) * 2016-10-05 2023-01-11 ユーイーエー エンタープライジズ リミテッド 癌の分類および予後
JP7539443B2 (ja) 2016-10-05 2024-08-23 ユーイーエー エンタープライジズ リミテッド 癌の分類および予後
JP2021173529A (ja) * 2020-04-17 2021-11-01 合同会社H.U.グループ中央研究所 胆管がんのバイオマーカー
JP7471898B2 (ja) 2020-04-17 2024-04-22 合同会社H.U.グループ中央研究所 胆管がんのバイオマーカー

Also Published As

Publication number Publication date
GB201320061D0 (en) 2013-12-25
US20160320395A1 (en) 2016-11-03
EP3069142A2 (en) 2016-09-21
CA2928510A1 (en) 2015-05-21
WO2015071669A2 (en) 2015-05-21
WO2015071669A3 (en) 2015-09-17

Similar Documents

Publication Publication Date Title
JP2016538545A (ja) 肝臓癌の診断及び予後判定のための材料及び方法
Alaiya et al. Clinical cancer proteomics: promises and pitfalls
JP6759229B2 (ja) 前立腺癌の診断および処置におけるフィラミンaを含むマーカーの使用
US10345309B2 (en) Biomarkers for gastric cancer and uses thereof
JP6786499B2 (ja) 膵癌のバイオマーカー
Zhou et al. Overexpression of PrPc, combined with MGr1‐Ag/37LRP, is predictive of poor prognosis in gastric cancer
WO2021076036A1 (en) Apparatuses and methods for detection of pancreatic cancer
KR101690249B1 (ko) 암의 진단 방법 및 암 환자의 전반적 생존 및 무질병 생존의 측정 방법
US20200249235A1 (en) Methods for diagnosing pancreatic cancer
JP6857185B2 (ja) 非小細胞肺癌診断用タンパク質バイオマーカーパネル及びこれを用いた非小細胞肺癌診断方法
JP2008527351A (ja) 前立腺癌のバイオマーカーとしてのアポリポタンパク質a−iiアイソフォーム
JP2018535433A (ja) デンスブレストを有する女性における乳癌の検出のためのバイオマーカー
KR102000387B1 (ko) 췌관내유두상점액종양의 악성도를 감별할 수 있는 단백질 바이오마커 및 그 용도
Sanchez-Carbayo Antibody array-based technologies for cancer protein profiling and functional proteomic analyses using serum and tissue specimens
WO2019115679A1 (en) A signature to assess prognosis and therapeutic regimen in liver cancer
KR102131860B1 (ko) 아르기닌이 메틸화된 ggt1에 특이적으로 결합하는 대장암 진단용 바이오마커 조성물
KR102136643B1 (ko) 신규한 간암 진단 마커 및 이의 용도
US20240402177A1 (en) Protein markers for estrogen receptor (er)-positive luminal a (la)-like and luminal b1 (lb1)-like breast cancer
CN111208304B (zh) 肿瘤来源IgG在甲状旁腺癌诊断和预后中的用途
US20250116676A1 (en) Phosphopeptide/phosphoprotein signature predicting basal-like breast cancer recurrence
Hanash et al. Deciphering the complexity of the cancer proteome for diagnostic applications
CA3214833A1 (en) Protein markers for the prognosis of breast cancer progression
CN118661103A (zh) 雌激素受体(er)阳性样和雌激素受体(er)阴性样乳腺癌的蛋白质标志物
Sanchez-Carbayo Discovery of cancer biomarkers using antibody arrays
Hussain et al. Proteomic biomarker discovery: review of the science and its challenges with clinical samples.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180228

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180822

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180918

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181214

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190604